PRA Health Sciences Stock Price, News & Analysis (NASDAQ:PRAH)

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings data on Wednesday, July, 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.11. The medical research company had revenue of $763.31 million for the quarter, compared to the consensus estimate of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The company's quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 EPS. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $4.98-5.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.01. The company issued revenue guidance of $3.02-3.1 billion, compared to the consensus revenue estimate of $3.1 billion.

10 analysts have issued 1-year price objectives for PRA Health Sciences' shares. Their predictions range from $100.00 to $126.00. On average, they expect PRA Health Sciences' stock price to reach $116.3750 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended somewhat negative on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for PRA Health Sciences.

PRA Health Sciences saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 2,193,000 shares, an increase of 19.8% from the July 15th total of 1,830,800 shares. Based on an average daily volume of 609,200 shares, the short-interest ratio is presently 3.6 days. Approximately 3.7% of the shares of the company are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Applied Materials (AMAT), Adobe (ADBE), Paypal (PYPL), Lam Research (LRCX), Netflix (NFLX), Veeva Systems (VEEV), Splunk (SPLK) and GrubHub (GRUB).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.67%), BlackRock Inc. (9.27%), BlackRock Inc. (9.27%), Price T Rowe Associates Inc. MD (7.14%), AQR Capital Management LLC (3.08%) and Bank of New York Mellon Corp (2.46%). Company insiders that own PRA Health Sciences stock include David W Dockhorn, Fund Holdings LP Kkr, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Jennison Associates LLC, Jennison Associates LLC, Carillon Tower Advisers Inc., Eagle Asset Management Inc., First Trust Advisors LP, Morgan Stanley and BlackRock Inc.. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Atria Investments LLC, Invesco Ltd., AQR Capital Management LLC, Marshall Wace LLP, Sloane Robinson LLP and Magnetar Financial LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $105.11.

PRA Health Sciences has a market capitalization of $6.92 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]